Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to boost statin use with simple doctor nudges

NCT ID NCT05537064

Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two methods to increase referrals to a centralized pharmacy service for managing statin therapy in patients with or at high risk for heart disease. One method sends reminders to doctors during office visits, and the other sends electronic messages outside of visits. The goal is to see if these nudges help more eligible patients get prescribed a statin, a common cholesterol-lowering medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention (nudge messages to doctors)
What this could lead to
If successful, this could show simple ways to help more patients get the right cholesterol medication, potentially reducing heart attacks and strokes.
What could go wrong
This is a pilot study testing methods to increase referrals, not a direct test of a new drug. Results may not apply to other settings, and the impact on actual health outcomes is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,950 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary Care Providers with at least 10 patients among their entire panel who meet the following criteria: * Have a LGH PCP, AND * 21-75 years old, AND * An indication for high- or moderate-intensity statin, AND * Pooled cohort risk equation 10-year ASCVD risk greater than 10%, OR * diabetes mellitus, OR * very high LDL-C \> 190 mg/dL, OR * familial hyperlipidemia, OR * established ASCVD, * Not currently on statin therapy, OR on low dose-statin therapy Exclusion Criteria: * Have an allergy to statins * Severe renal insufficiency defined as glomerular filtration rate (GFR) less than 30 mL/min or on dialysis * Adverse reaction to statins including statin-related a) myopathy; b) Rhabdomyolysis; c) hepatitis * Pregnant * Currently breastfeeding * On hospice or at the end-of-life * On a PCSK9 Inhibitor medication * Physicians (and their respective patients) will be excluded if they have less than 10 patients among their entire panel that are eligible for a statin medication.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic vascular disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperlipidemias

Contacts and locations

Locations

  • Lancaster General Hospital

    Lancaster, Pennsylvania, 17602, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.